The Autogenous Vaccines Market To Be Resplendent At A CAGR Of 4.4%

Posted by Merin John on April 9th, 2021

Vaccination of animals is an essential part of animal health management. It helps to boost the immune system and keep animals safe from various bacterial and viral infections. Autogenous vaccines are most preferred for animal vaccination purposes. Federal guidelines state that an autogenous vaccine is made from a bacterial or viral strain of the diseased animal. Products made from these strains can only be marketed by veterinarian or farm owners from where they were isolated.

Over the years, there has been growing demand for autogenous vaccines that are derived from bacterial strains, owing to their greater efficacy as compared to viral strains. Salmonella, Staphylococcus, Haemophilus, and Mycoplasma are some of the commonly used bacterial strains to develop autogenous bacterial vaccines. Growing prevalence of bacterial infections among animals, preference toward autogenous vaccines over antibiotics, and increased funding and support for international animal disease eradication are likely to upswing demand for autogenous bacterial vaccines over the coming years.

According to a revised report published by Persistence Market Research, the autogenous vaccines market was valued over US$ 116 Mn in 2020, and is predicted to witness an impressive CAGR of 5.5% over the forecast period (2021-2031).

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/29491

Companies covered in Autogenous Vaccines Market Report

Newport Laboratories, Inc. (Boehringer Ingelheim International GmbH)

Phibro Animal Health

Elanco Animal Health

Ceva Santé Animale

ACE Laboratory Services (Apiam Animal Health)

Huvepharma, Inc.

AniCon Labor GmbH

Cambridge Technologies

Dyntec s. r. o

Hygieia Biological Laboratories

HIPRA

Vaxxinova

sanphar (ipeve)

Addison Biological Laboratory

Zoetis (PHARMAQ AS)

Barramundi Asia Pte Ltd.(UVAXX Asia)

Kennebec River Biosciences

 Key Takeaways from Market Study

By type of strain, bacterial autogenous vaccines are expected to contribute to more than 1/3 revenue share in the market.

By end user, livestock farming companies will lead by acquiring over 45% of market share. This sector has witnessed the most adoption of autogenous vaccines as compared to other end users.

Europe holds around half of the global market share.

Key players are focused on expanding their product portfolios and expansion at regional levels through collaborations and acquisitions.

COVID-19 outbreak in big economies is expected to negatively impact demand for autogenous vaccines owing to reduced healthcare center visits. Impact was also observed on vaccine production and transportation owing to travel restriction and lack of workforce at production centers.

The market in Thailand is projected to be the fastest-growing in the Asia Pacific region, and will expand at a CAGR above 5% through 2031.

The U.S. market holds a big portion of revenue, and its market share accounts for more than 90% in North America.

“Increasing preference for autogenous vaccines over antibiotics will catalyze market growth over the coming years,” says an analyst of Persistence Market Research.